منابع مشابه
Ongoing trials in low-grade lymphoma
There are many therapies available for the management of low-grade lymphoma. With follicular lymphoma, for example, combination of chemotherapy and rituximab (immuno-chemotherapy) and consecutive maintenance therapy for 2 years is the current standard of care. To date, the most widely used regimen seems to be rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-...
متن کاملLow-grade lymphoma.
Folicular lymphoma (FL), the second most common subtype of non-Hodgkin lymphoma, shows considerable heterogeneity in its clinical behavior, representative of a biology that appears increasingly complex and diverse. As our knowledge of the molecular basis of FL increases, we strive for an integration between the bench and clinic that yields treatments based on our scientific understanding and bi...
متن کاملLow-grade lymphoma: Beyond fludarabine-single therapy
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. http://dx.doi.org/10.5045/kjh.2011.46.3.145 The Korean Journal of Hematology Volume 46ᆞNumbe...
متن کاملBexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma.
PURPOSE Immunotherapy using monoclonal antibodies to specifically target B cells has provided new hope to many patients with indolent lymphomas, particularly those with chemotherapy-refractory disease. Lymphomas are extremely sensitive to radiation, and significant progress has been made over the last decade in the development of radioimmunotherapy with anti-CD20 antibodies. MATERIALS AND MET...
متن کاملOngoing Acute Endovascular Stroke Trials
With the failure of multiple recent acute stroke trials to show the benefit of endovascular treatment, there has been a lot written and spoken about next steps. In the wake of these results, many new trials have started with slightly varying principles, selection criteria, and depending on their sponsor, different devices. All these trials have tried to overcome the design limitations of the pr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hematology Reports (formerly Hematology Reviews)
سال: 2011
ISSN: 2038-8330,2038-8322
DOI: 10.4081/hr.2011.s3.e5